Diego Ripamonti

8PUBLICATIONS
35CO-AUTHORS
Gene and molecular therapyMedical molecular engineering of nucleic acids and proteinsBehavioural epidemiologyDisease surveillanceCentral nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 14, 2026
VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment.

|Sep 23, 2025
Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.

Josep M Llibre, Diego Ripamonti, Anna M Geretti

|Apr 09, 2025
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study).

Diego Ripamonti, Laura Comi, Andrea Francavilla

|Feb 10, 2025
Durability of doravirine/dolutegravir dual combination in a multicentre cohort of elderly people with HIV.

Maria Mazzitelli, Claudia Cozzolino, Cristina Gervasoni

|Aug 22, 2024
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study.

Andrea Calcagno, Jessica Cusato, Paola Cinque

|Sep 27, 2023
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.

Elena Bruzzesi, Arianna Gabrieli, Davide Bernasconi

Pageof 2

Frequent Collaborators

2 joint publications

Andrea Calcagno

2 joint publications

Raquel Martin-Iguacel

2 joint publications

Silvia Nozza

2 joint publications

Stefano Rusconi